Abbott Laboratories (ABT) – Declining demand for COVID 19 tests

Abbott had hoped to maintain Covid test sales with the release of BinaxNOW for over the counter
sales and home use. But as U.S. vaccination rates grow, infections wane and pandemic restrictions loosen, use of the assays has declined.

Highlights

Valuation

– Enterprise Value
– CrispIdea Forecast.
– Economic Value Added Analysis
– DCF Analysis
– P/E Analysis
– Peer Valuation
– CrispIdea Forecast Relative to Consensus
– Consensus History and Surprise
– Consensus Momentum

Actual & Historical Performance

– Income Statement
– Balance Sheet
– Cash Flow
– 10 Year Historical Performance
– Ratio Analysis
– Du Pont Analysis
– ROIC & ROCE Analysis
– Segment Performance
– M&A Deals

Peer Performance

– Summary
– Profitability
– Growth
– Price Performance

Ownership

Stock Price Performance

CrispIdea Coverage

No of Pages : 36